A detailed history of Nations Financial Group Inc, transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Nations Financial Group Inc, holds 3,755 shares of VRTX stock, worth $1.79 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
3,755
Previous 3,788 0.87%
Holding current value
$1.79 Million
Previous $1.58 Million 11.18%
% of portfolio
0.15%
Previous 0.14%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$392.81 - $485.53 $12,962 - $16,022
-33 Reduced 0.87%
3,755 $1.76 Million
Q1 2024

Apr 23, 2024

BUY
$407.69 - $446.08 $190,798 - $208,765
468 Added 14.1%
3,788 $1.58 Million
Q4 2023

Feb 09, 2024

BUY
$343.0 - $410.68 $15,435 - $18,480
45 Added 1.37%
3,320 $1.35 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $49,036 - $52,556
145 Added 4.63%
3,275 $1.14 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $5,030 - $5,630
16 Added 0.51%
3,130 $1.1 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $24,641 - $28,109
87 Added 2.87%
3,114 $981,000
Q4 2022

Feb 07, 2023

SELL
$285.76 - $321.48 $44,292 - $49,829
-155 Reduced 4.87%
3,027 $874,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $203,729 - $227,314
-744 Reduced 18.95%
3,182 $921,000
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $26,550 - $33,058
113 Added 2.96%
3,926 $1.11 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $302,238 - $356,224
1,365 Added 55.76%
3,813 $995,000
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $433,320 - $547,005
2,448 New
2,448 $538,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $315,897 - $421,313
-1,526 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $390,121 - $462,530
1,526 New
1,526 $415,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Nations Financial Group Inc, Portfolio

Follow Nations Financial Group Inc, and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nations Financial Group Inc, , based on Form 13F filings with the SEC.

News

Stay updated on Nations Financial Group Inc, with notifications on news.